Eli Lilly disclosed positive Phase 3 Attain‑Maintain results showing its oral GLP‑1 candidate, orforglipron, helped patients maintain weight after prior treatment with injectable GLP‑1 therapies. Lilly reported the trial met the primary and key secondary endpoints over 52 weeks, with better weight maintenance versus placebo. The company has formally filed for regulatory review and received a 'national priority' voucher expected to speed the decision. Results could broaden the market for oral obesity therapeutics and challenge injectable incumbents by offering a maintenance option with potential adherence advantages.